O' Kane Rebecca, Hathorn Emma
Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Frontline Gastroenterol. 2023 Jun 13;14(5):415-421. doi: 10.1136/flgastro-2022-102373. eCollection 2023.
Hepatitis B virus and hepatitis C virus (HCV) remain leading causes of disability and premature death worldwide. In May 2016, the UK, as a member of the World Health Assembly, adopted the Global Health Sector Strategy and its targets to eliminate viral hepatitis as a public health threat by 2030. In pursuit of this goal, there have been a number of recent advances in viral hepatitis care. Perhaps most notable is the availability of short courses of all-oral curative direct acting antivirals for hepatitis C. However, while access to treatment has been scaled up across the UK, an estimated 93 000 people were still living with HCV at the end of 2021 of which three-quarters remained unaware of their infection. This review article will summarise key advances in hepatitis C treatment and prevention and provide a practical approach to the management of individuals living with hepatitis C infection.
乙型肝炎病毒和丙型肝炎病毒(HCV)仍是全球残疾和过早死亡的主要原因。2016年5月,英国作为世界卫生大会的成员,通过了《全球卫生部门战略》及其目标,即到2030年消除病毒性肝炎这一公共卫生威胁。为实现这一目标,病毒性肝炎护理领域最近取得了一些进展。或许最值得注意的是丙型肝炎全口服直接作用抗病毒药物短疗程疗法的出现。然而,尽管英国各地扩大了治疗的可及性,但据估计,截至2021年底仍有9.3万人感染丙型肝炎病毒,其中四分之三的人仍未意识到自己已感染。这篇综述文章将总结丙型肝炎治疗和预防方面的关键进展,并提供一种针对丙型肝炎感染患者管理的实用方法。